LLYEli Lilly and CompanyRunning, no new patients
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Breast Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 669 (final count)
- Started
- Jul 22, 2014
- Main results expected
- Feb 14, 2017
- Fully finished
- Dec 2027
- Results posted
- Mar 13, 2018
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02107703 · record last updated 2026-10-14 · checked 2026-11-09 15:36 UTC